DOCSLIB.ORG

Business Acceleration Manager- Medicity Scotland Overview

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Business Acceleration Manager- MediCity Scotland Location: BioCity Scotland campus, Newhouse, Scotland Full time, permanent. Salary: competitive, plus participation in BioCity Group employee share option scheme Overview BioCity Group is seeking a dynamic, entrepreneurial person to lead its company creation and accelerator programme activities at its new medical technology incubator near Glasgow. The successful candidate will join the wider BioCity Group team and benefit from the opportunities and rewards arising from being part of this fast growing business. Background The BioCity Group is dedicated to channelling entrepreneurship to meet the world’s healthcare needs. We believe much of the innovation needed to tackle the challenges of an expanding and ageing population along with rising costs of care will come from new entrepreneurial companies. So at each of our locations we provide the best environment for these growing and ambitious life science businesses to maximise their chances of success. BioCity was first established in Nottingham in 2003. It was one of the first incubators offering laboratories alongside business support to early stage companies in the life science sector. Since then, the BioCity Group has grown to include locations in Cheshire, Scotland and Nottingham and has launched MediCity in Nottingham and now Scotland. Whilst in the early years the facilities at BioCity led to a focus on companies in drug discovery and delivery, therapeutics and medical devices, the launch of MediCity widens the type of companies to also include, alongside med tech, the areas of digital health, well-being and beauty. The first MediCity facility, MedCity Nottingham, opened in early 2014 and already has more than 30 companies within its community. MediCity Nottingham is based within the former Boots Healthcare International facility, at the heart of the Walgreens Boots Alliance campus, a new Enterprise Zone in Nottingham. With the support of Walgreens Boots Alliance, our partner in MediCity Nottingham, our goal is to grow MediCity to become the global innovation leader for medical technology and related businesses with the recognition of the Newhouse facility as the premier hub in Scotland. MediCity Scotland has approximately 12,000 sq ft of newly refurbished space in which to house businesses. These will range from established companies seeking to be part of the medtech ecosystem created at MediCity, to very early stage businesses or pre-start-ups using hot desks and meeting rooms. The facility includes workshops/labs, offices, meeting rooms and individual workstations. BioCity and MediCity now house over 200 companies. There is a 91% survival rate over 12 years of companies at BioCity Nottingham and Mobius, our internal investment fund, has 6.7x return. BioCity Group has created a suite of accelerator programmes and activities to ensure the ongoing creation and success of companies at the BioCity and MediCity sites. 1 Accelerator Programmes The BioCity/MediCity Innovation Engine is made up of 4 stages of accelerator programme namely; Spark, Develop, Launch and Xcel. It is designed to help drive companies from earliest stage to rapid growth and, where appropriate, final exit. The goal of the programmes is to increase the number and quality of start-ups being created and subsequently housed and financed by and growing in the facilities at BioCity/MediCity. The 4 stages of the Innovation Engine are; Spark – themed and curated, business ideation and networking, events to help increase the likelihood of start-ups; Develop – 13 week programme that harnesses tools like ‘Business Model Canvas’ and ‘Lean Start-up’ to provide robust challenge and improved customer discovery to early stage ideas; Launch – 10 week programme that helps the more developed opportunities become business ready and investment ready; Xcel – teaching and coaching entrepreneurial excellence for company growth. These activities are intrinsically linked to, and will facilitate investments from, the Alderley Park Ventures Fund and Mobius Venture Fund, the 2 early stage investment funds run by BioCity. The Role You will lead the accelerator programme and business coaching activities at MediCity Scotland. Your role will be integral to building the MediCity Scotland incubator into Scotland’s leading centre for the development of healthcare and medical technology companies by driving and supporting the creation and growth of early stage businesses in the sector. You will work with and be supported by the coaching teams at the other sites while also benefiting from the experience and support infrastructure of the BioCity Group. However, you will have primary responsibility for: • The delivery of all programmes at MediCity Scotland i.e. o Spark – Establish a targeted annual events programme with a focus on innovation in health and wellbeing and a particular emphasis on medtech o Develop – Run 2 Develop programmes per year with 6-10 participant businesses o Launch – Run in conjunction with the other sites a Launch programme (min 1 per year) o Xcel – Ongoing programmes and coaching delivered according to the needs of the tenant companies • Recruitment of coaches to provide full time or ad hoc support to businesses at MediCity and on the start-up programmes • Recruitment of participants to the programmes of the requisite number and quality • The ongoing evolution of the content and delivery of the different programmes • Staying up to date with latest start-up tools and techniques from all sectors and geographies • Liaising with other BioCity Group coaches to share best practice, content development and coaching techniques and provide best possible support to participant companies • Working closely with all partners including Scottish Enterprise, large pharma and healthcare, end user groups, investors, university tech transfer offices and business schools, NHS and existing, networks, events and programmes • Monitoring and reporting for the financial and key performance indicators of the programmes and ensuring any requirements of any public sector funding are met • Working closely with Alderley Park and Mobius Investment Managers to ensure the programme delivers an ongoing pipeline of high quality investment opportunities • Working closely with the Incubator Manager to ensure new companies are suitably housed and existing companies suitably supported 2 • Facilitating the transition of early-stage companies into Scottish Enterprise’s High Growth Programme Skills and Experience The successful candidate will require: • A passion for helping entrepreneurs succeed • Confident and convincing presentation skills • Strong focus on process and strong project management skills • Strong academic background • Understanding, if not direct experience, of starting a business and of the requirements of early stage investors • Knowledge of business start-up tools such as Value Proposition Canvas, Lean Start-up assumption testing and other ‘evidence based’ entrepreneurship tools • Experience of using other established business coaching and consultancy tools • Knowledge of accelerator programmes • Relevant experience of, ideally, the healthcare, medtech, diagnostics sectors or the biotech and pharmaceutical sectors The successful candidate should also have: • Ability to assess early stage business opportunities • Ability to communicate effectively with entrepreneurs and start up team • Credibility and communications skills required to engage with a range of partner organisations to involve them in the programmes • An understanding of and interest in personal coaching and behavioural change Candidate Profile The successful candidate(s) will likely have experience in some, if not all of, the following areas: start- ups, business coaching, management consultancy, early stage investment management and accelerator programmes and in some, if not all of, the following sectors: healthcare, med tech, biotech and/or pharmaceuticals. To Apply Please submit applications including a CV to: Lorna Richardson at [email protected] Include details of current salary/ salary expectations and notice period. Closing date: 11 September 2015 3 .
Recommended publications
  • Directory of Companies A

    Directory of Companies A

    65 Directory of Companies A An alphabetical list of pharmaceutical companies, as well as manufacturers and suppliers of products and services for Medicinal Chemistry in Europe 3B PHARMACEUTICALS GMBH Magnusstraße 11 12489 BERLIN DE 3M BELGIUM Canadastraat 11, Haven 1005 2070 ZWIJNDRECHT BE 3V-LSI Rubicondreef 18 3561 JC UTRECHT NL of Companies 4SC AG Am Klopferspitz 19a 82152 MARTINSRIED DE A & D INSTRUMENTS LTD Abingdon Science Park OX14 3YX ABINGDON GB ABBVIE DEUTSCHLAND GMBH & CO. KG Knollstrasse 67061 LUDWIGSHAFEN DE Directory ABCR GMBH Im Schlehert 10 76187 Karlsruhe, GERMANY Contact person: Dr. Ute Kiso Tel: +49 721 95061-0 - [email protected] www.abcr.de Gute Chemie. Welcome to abcr. With abcr, you have access to over 260,000 products from the organic, organometallic and inorganic specialty chemicals area. These can be conveniently ordered via our webshop www.abcr.de > Catalogue & Bulk business from grams to tons > Scale up & Commercial manufacturing from our own facility > Sourcing & Logistic management worldwide > Feasibility studies & Synthesis at the laboratory scale > Custom syntheses & Contract Manufacturing ABSORPTION SYSTEMS 440 Creamery Way Suite 300 PA 19341 EXTON US AC IMMUNE SA EPFL Innovation Park Building B 1015 LAUSANNE FR ACCELA CHEMBIO 9823 Pacific Heights Blvd # F 92121 SAN DIEGO US ACRAF S.P.A. Piazzale della Stazione 40 S. PALOMBA - POMEZIA IT ACROS ORGANICS Janssen Pharmaceuticalaan 3a 2440 GEEL BE ACS Journal of Medicinal Chemistry & ACS Medicinal Chemistry Letters Contact person: Janice E. Silverman, Acquisitions Editor Tel: +1 202-577-5975 [email protected] Journal of Medicinal Chemistry – pubs.acs.org/jmc ACS Medicinal Chemistry Letters – pubs.acs.org/acsmedchemlett In 2017 Journal of Medicinal Chemistry is celebrating 60 years of publishing the field’s best peer-reviewed research.
  • Contents Page

    Contents Page

    Statement of Development Principles: Regeneration Of Boots Campus, Beeston, Nottingham June 2007 STATEMENT OF DEVELOPMENT PRINCIPLES: REGENERATION OF BOOTS CAMPUS, BEESTON, NOTTINGHAM (June 2007) Contents 1. Introduction................................................................................................2 PURPOSE.............................................................................................................................. 2 POLICY CONTEXT................................................................................................................ 3 2. Development Principles ............................................................................4 THE VISION........................................................................................................................... 4 KEY DEVELOPMENT PRINCIPLES ..................................................................................... 4 3. Key Issues ..................................................................................................7 HIGHWAYS AND ACCESS ................................................................................................... 7 BALANCE OF USES ............................................................................................................. 7 LISTED BUILDINGS .............................................................................................................. 9 ENVIRONMENT.....................................................................................................................9
  • Acacia Pharma Group

    Acacia Pharma Group

    This document comprises a prospectus (the “Prospectus”) relating to Acacia Pharma Group plc (the “Company” or “Acacia Pharma”) prepared in accordance with the prospectus regulation rules (the “Prospectus Regulation Rules”) of the UK Financial Conduct Authority (the “FCA”) made pursuant to section 73A of the Financial Services and Markets Act 2000, as amended (“FSMA”). This Prospectus has been approved by the FCA as the competent authority under Regulation (EU) 2017/1129 (the “Prospectus Regulation”) and has been filed with and made available to the public in accordance with Rule 3.2 of the Prospectus Regulation Rules. The FCA only approves this Prospectus as meeting the standards of completeness, comprehensibility and consistency imposed by the Prospectus Regulation. Such approval should not be considered as an endorsement of the Company or of the quality of the Ordinary Shares that are the subject of this Prospectus. Investors should make their own assessment as to the suitability of investing in the Ordinary Shares. In addition, this Prospectus has been drawn up as a simplified prospectus in accordance with Article 14 of the Prospectus Regulation. The Belgian Financial Services and Markets Authority (“Belgian FSMA”) was notified of the passporting of this Prospectus in accordance with Article 25 of the Prospectus Regulation. The Company and the Directors, whose names appear on page 39 of this document, accept responsibility for the information contained in this document. To the best of the knowledge of the Company and the Directors, the information contained in this document is in accordance with the facts and this document makes no omission likely to affect its import.
  • All Together. Different. Svi Zajedno

    All Together. Different. Svi Zajedno

    Diversity & Inclusion Report 2018–19 All Together. Different. Svi zajedno. Različiti. • Všichni společně. • Každý jiný. • Eensgezind. Anders. • Tous ensem- ble, tous différents. • Einträchtig. Anders. • Tut- ti assieme, ma diversi. • Visi kartu. Skirtingi. • Alle sammen. Forskjellige • Todos juntos. TableDifer of Contents- Deepening Our Diversity and Inclusion entes. • Împreună. Diferiți • Hep birlikte. FaEmphasisrklı. ............................................... 1 • Svi zajedno. Različiti. • Všichni společněMessages. • from Our CEO, Global Chief Human Resources Officer and Our Global Každý jiný. • Eensgezind. Anders. • Tous enChief -Diversity Officer ........................2–3 Our D&I Impact Is Expansive semble, tous différents. • Einträchtig. Anderand Expandings. • ...................................... 4 WBA Strengthens Its D&I Strategy, Tutti assieme, ma diversi. • Visi kartu. SkirtiData Collectionngi. ............................... 6–13 Our Business Resource Groups Foster Inclusive Global Cultures ................ 14–21 All Together. Different. Împreună. Diferiți • Expanding Business Opportunities Todos juntos. Diferentes. • Hep birlikte. Farklby Attracting,ı. Nurturing Diverse Suppliers .......................... 22–25 • Svi zajedno. Različiti. • Všichni společně.WBA • Earns Wide Recognition for D&I Leadership ........................ 26–27 Každý jiný. • Eensgezind. Anders. • Tous ensemLooking Ahead ....................................- 29 ble, tous différents. • Einträchtig. Anders. • Tut- ti assieme, ma diversi. • Visi kartu.
  • Corporate Social Responsibility Report 2016 Walgreens Boots Alliance Is the First Global Pharmacy-Led, Health and Wellbeing Enterprise

    Corporate Social Responsibility Report 2016 Walgreens Boots Alliance Is the First Global Pharmacy-Led, Health and Wellbeing Enterprise

    Corporate Social Responsibility Report 2016 Walgreens Boots Alliance is the first global pharmacy-led, health and wellbeing enterprise. Our purpose is to help people across the world lead healthier and happier lives. Our 2016 Corporate Social Responsibility Report covers the fiscal year that ended 31 August 2016. In this year’s report: Overview Marketplace Introduction ...................................................1 Our CSR goals .............................................2 28 Our vision, purpose and values ................3 Our approach to CSR .................................4 Contributing to the United Nations Sustainable Development Goals .............6 Transparency ........................................... 30 Our impact ...................................................8 Ethical Sourcing ...................................... 30 ........................... About our Company ................................. 10 External Stakeholders 31 Stakeholder engagement ....................... 12 Workplace Community 32 14 Employee Health and Wellbeing ........ 34 Equal Opportunities .............................. 36 Health and Wellbeing ............................. 16 Health and Safety ...................................37 Young People ........................................... 17 ...................................... Cancer Programs .....................................20 About this report 38 Data management process ................ 38 Environment Data ............................................................ 38 Community data
  • A Science and Innovation Audit Report for the Midlands Engine

    A Science and Innovation Audit Report for the Midlands Engine

    A Science and Innovation Audit Report for the Midlands Engine, sponsored by the Department for Business, Energy & Industrial Strategy Volume 1: Main Report 01 November 2016 A Science and Innovation Audit Report for the Midlands Engine, sponsored by the Department for Business, Energy & Industrial Strategy Volume 1: Main Report Contents Midlands Engine SIA – the headlines ....................................................................................1 1. Introduction to the Midlands Engine SIA...........................................................................4 2. SIA ‘hypotheses’ and ‘framework’ ...................................................................................10 3. Regional science and innovation assets and excellence..............................................19 4. Innovation strengths and our growth priorities..............................................................30 5. Market and technology drivers of change.......................................................................53 6. Innovation networks and behaviours ..............................................................................59 7. Next Steps – unlocking our productivity potential.........................................................67 A Science and Innovation Audit Report for the Midlands Engine, sponsored by the Department for Business, Energy & Industrial Strategy Volume 1: Main Report Midlands Engine SIA – the headlines 1. In Autumn 2015 the UK Government announced regional Science and Innovation Audits (SIAs) to catalyse
  • A Preclinical Evaluation of the Discriminative And

    A Preclinical Evaluation of the Discriminative And

    NP5101_proof ■ 12 June 2013 ■ 1/11 Neuropharmacology xxx (2013) 1e11 Contents lists available at SciVerse ScienceDirect Neuropharmacology journal homepage: www.elsevier.com/locate/neuropharm 1 56 2 A preclinical evaluation of the discriminative and reinforcing 57 3 58 4 properties of lisdexamfetamine in comparison to D-amfetamine, 59 5 fi 60 6 methylphenidate and moda nil 61 7 62 a,* a a a b 8 Q5 David J. Heal , Niki W. Buckley , Jane Gosden , Nigel Slater , Charles P. France , 63 9 David Hackett c 64 10 65 a 11 RenaSci Ltd, BioCity Nottingham, Pennyfoot Street, Nottingham NG1 1GF, UK 66 b University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900, USA 12 c Shire Pharmaceutical Development Ltd, Hampshire International Business Park, Chineham, Basingstoke RG24 8EP, Hampshire, UK 67 13 68 14 69 15 article info abstract 70 16 71 17 Article history: Lisdexamfetamine dimesylate, which consists of L-lysine covalently bound to D-amfetamine, is the first 72 18 Received 12 December 2012 prodrug for treating ADHD. Its metabolic conversion to yield D-amfetamine by rate-limited, enzymatic 73 19 Received in revised form hydrolysis is unusual because it is performed by peptidases associated with red blood cells. Other 74 3 April 2013 20 stimulants shown to be effective in managing ADHD include D-amfetamine, methylphenidate and 75 Accepted 13 May 2013 21 modafinil. All have the potential for misuse or recreational abuse. The discriminative and reinforcing 76 effects of these compounds were determined in rats using a 2-choice, D-amfetamine (0.5 mg/kg, i.p.)- 77 22 Keywords: cued drug-discrimination test, and by substitution for intravenous cocaine in self-administration.
  • At the Heart of Health Corporate Social Responsibility Report

    At the Heart of Health Corporate Social Responsibility Report

    2020 At the Heart of Health Corporate Social Responsibility Report #WeAreWBA We are a leading global pharmacy retailer and wholesaler. As a health and well-being enterprise our purpose is to help people across the world lead healthier and happier lives. At the Heart of Health is our annual Corporate Social Responsibility report, covering our CSR initiatives, sustainability progress and Environmental, Social and Governance (ESG) performance for the fiscal year ended Aug. 31, 2020. OVERVIEW HEALTHY PLANET Message from Our Leaders 4 Energy and Emissions 85 Q&A with Our CSR Committee Chair 6 Waste and Plastics 94 Our Vision, Purpose and Values 8 Case Study: Honeybees on Campus 100 At a Glance: WBA 9 SUSTAINABLE MARKETPLACE Highlights and Recognitions 10 Progress Dashboard 12 Sustainability Progress in Our Owned Brands 103 Our Approach to CSR 15 Sourcing 106 CSR Materiality 24 Ingredients, Materials and Traceability 111 Stakeholder Engagement 28 Packaging, Labeling and Transparency 114 Our Response to COVID-19 38 Case Study: Removing Plastics from Boots UK Gift Product Lines 117 Our Response to the Racial Equity Movement 46 Brands with Purpose 118 HEALTHY AND INCLUSIVE WORKPLACE HEALTHY COMMUNITIES Employee Health, Well-being and Safety 123 Access to Affordable and Quality Healthcare 51 Equal Opportunities 134 Health Education and Awareness 61 Case Study: Unconscious Bias Training 145 Opioid Abuse Prevention 70 Data Privacy and Information Security 146 Partnerships for Good: 71 APPENDICES Supporting People Living with Cancer 72 About This Report
  • BIO-SCIENCE FACILITY, LOWER PARLIAMENT STREET, NOTTINGHAM Nottingham City Council Lease the OPPORTUNITY

    BIO-SCIENCE FACILITY, LOWER PARLIAMENT STREET, NOTTINGHAM Nottingham City Council Lease the OPPORTUNITY

    Significant Capital Allowance Investment Opportunity BIO-SCIENCE FACILITY, LOWER PARLIAMENT STREET, NOTTINGHAM Nottingham City Council Lease THE OPPORTUNITY Unique opportunity to acquire a new bio-science incubator facility let on a long lease to a major city council with significant capital allowances providing an attractive post tax return. Prominently located at Lower Parliament Street, Nottingham There are estimated £9,750,000 of available capital allowances to a adjacent to the existing Bio-City buildings within Nottingham’s purchaser which at a higher tax rate of 45% are worth £4,387,500 creative quarter. over a 5 year period. 150 years long-leasehold interest at a peppercorn rent from Nottingham City Council is to provide a loan to the purchaser of Nottingham City Council. £11,011,200 for a 5 years period at a fixed interest rate of 4.50% which equates to £495,484 interest per annum. No amortisation required during this period. Construction commenced in August 2015 on the new Biocity Science building over ground and 4 upper floors providing state of the art laboratory and office accommodation and extending to 52,475 sq ft Purchaser equity requirement of £6,748,800 which after interest NIA. Willmott Dixon is the appointed contractor. charges provides a net annual pre tax yield of 3.18%. To be let to Nottingham City Council for 30 years from completion of this transaction on a full repairing and insuring lease at an initial rent of Post tax annual yields are Year 1 - 7.54%, Year 2 - 6.86%, Year 3 - £714,000 per annum equating to £13.61 per sq ft.
  • Distributor Settlement Agreement

    Distributor Settlement Agreement

    DISTRIBUTORS’ 7.30.21 EXHIBIT UPDATES DISTRIBUTOR SETTLEMENT AGREEMENT DISTRIBUTORS’ 7.30.21 EXHIBIT UPDATES Table of Contents Page I. Definitions............................................................................................................................1 II. Participation by States and Condition to Preliminary Agreement .....................................13 III. Injunctive Relief .................................................................................................................13 IV. Settlement Payments ..........................................................................................................13 V. Allocation and Use of Settlement Payments ......................................................................28 VI. Enforcement .......................................................................................................................34 VII. Participation by Subdivisions ............................................................................................40 VIII. Condition to Effectiveness of Agreement and Filing of Consent Judgment .....................42 IX. Additional Restitution ........................................................................................................44 X. Plaintiffs’ Attorneys’ Fees and Costs ................................................................................44 XI. Release ...............................................................................................................................44 XII. Later Litigating
  • At the Heart of Health Corporate Social Responsibility Report

    At the Heart of Health Corporate Social Responsibility Report

    2020 At the Heart of Health Corporate Social Responsibility Report #WeAreWBA We are a leading global pharmacy retailer and wholesaler. As a health and well-being enterprise our purpose is to help people across the world lead healthier and happier lives. At the Heart of Health is our annual Corporate Social Responsibility report, covering our CSR initiatives, sustainability progress and Environmental, Social and Governance (ESG) performance for the fiscal year ended Aug. 31, 2020. OVERVIEW HEALTHY PLANET Message from Our Leaders 4 Energy and Emissions 85 Q&A with Our CSR Committee Chair 6 Waste and Plastics 94 Our Vision, Purpose and Values 8 Case Study: Honeybees on Campus 100 At a Glance: WBA 9 SUSTAINABLE MARKETPLACE Highlights and Recognitions 10 Progress Dashboard 12 Sustainability Progress in Our Owned Brands 103 Our Approach to CSR 15 Sourcing 106 CSR Materiality 24 Ingredients, Materials and Traceability 111 Stakeholder Engagement 28 Packaging, Labeling and Transparency 114 Our Response to COVID-19 38 Case Study: Removing Plastics from Boots UK Gift Product Lines 117 Our Response to the Racial Equity Movement 46 Brands with Purpose 118 HEALTHY AND INCLUSIVE WORKPLACE HEALTHY COMMUNITIES Employee Health, Well-being and Safety 123 Access to Affordable and Quality Healthcare 51 Equal Opportunities 134 Health Education and Awareness 61 Case Study: Unconscious Bias Training 145 Opioid Abuse Prevention 70 Data Privacy and Information Security 146 Partnerships for Good: 71 APPENDICES Supporting People Living with Cancer 72 About This Report
  • Economic Strategy Research Bureau

    Economic Strategy Research Bureau

    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Nottingham Trent Institutional Repository (IRep) Biotechnology, life sciences and skills in D2N2: A report for Learn Direct and the D2N2 Local Enterprise Partnership Will Rossiter, David J. Smith, Nikolas Pautz, Daniel McDonald-Junor Economic Strategy Research Bureau Nottingham Business School Nottingham Trent University July 2018 2018 Contents Executive Summary............................................................................................................................ 4 1 Introduction ................................................................................................................................ 6 1.1 Approach ................................................................................................................................. 7 2 What are life sciences and the biotech industry? ....................................................................... 9 2.1 Origins of the Biotechnology industry .................................................................................. 10 2.2 Features of the emerging UK biotechnology industry .......................................................... 13 2.3 The Bioincubator boom of the 2000-2008 ............................................................................ 14 3 Restructuring, Open Innovation and Outsourcing in the Pharmaceutical Industry ................. 17 4 The Decline in Laboratory Technician training ........................................................................